Medscape: Promising Weight-Loss Compound Targets Energy Expenditure

An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could eventually be an alternative or add-on to popular GLP-1 medications.

EOLO PHARMA today announced that it has dosed the first subjects in Phase 1 clinical trials of MVD1, designed to prevent and treat obesity and its cardiometabolic complications.

An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could eventually be an alternative or add-on to popular GLP-1 medications.

Carlos Escande lidera desde 2013 el Laboratorio de Patologías del Metabolismo y el Envejecimiento. Llegó al instituto luego de ser seleccionado con el último llamado internacional para jóvenes líderes que tenía un fondo por cinco años con el objetivo de entender los mecanismos de evolución de las patologías del metabolismo como obesidad, diabetes y enfermedades cardiovasculares.

EOLO PHARMA today announced that it has dosed the first subjects in Phase 1 clinical trials of MVD1, designed to prevent and treat obesity and its cardiometabolic complications.

EOLO PHARMA announced that it has received approval to initiate a Phase 1 clinical trial for MVD1, the company’s investigational small molecule designed to reduce body weight and glucose levels in blood.